Portal de Periódicos da CAPES

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

2017; Elsevier BV; Volume: 130; Issue: 10 Linguagem: Inglês

10.1182/blood-2017-05-782961

1528-0020

Jonas Paludo, Joseph Mıkhael, Betsy LaPlant, Alese E. Halvorson, Shaji Kumar, Morie A. Gertz, Suzanne R. Hayman, Francis K. Buadi, Angela Dispenzieri, John A. Lust, Prashant Kapoor, Nelson Leung, Stephen J. Russell, David Dingli, Ronald S. Go, Yi Lin, Wilson I. Gonsalves, Rafaël Fonseca, P. Leif Bergsagel, Vivek Roy, Taimur Sher, Asher Chanan‐Khan, Sikander Ailawadhi, A. Keith Stewart, Craig B. Reeder, Paul G. Richardson, S. Vincent Rajkumar, Martha Q. Lacy,

Protein Degradation and Inhibitors

Key Points PVD is an active combination in relapsed lenalidomide-refractory MM patients. PVD with weekly bortezomib offers a simpler, more convenient, and well-tolerated regimen option.